Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MS1819,Porcine enzyme replacement therapy
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: AzurRx BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 07, 2020
Details:
Creapharm will package, label, and distribute AzurRx’s MS1819 clinical trial drug product for both the upcoming Phase 2b OPTION 2 Monotherapy and the ongoing Phase 2 Combination Therapy Programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MS1819
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: AzurRx BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 16, 2020
Details:
Under this agreement, Delpharm will manufacture AzurRx’s MS1819 cGMP batch that will be used in the Phase 2b OPTION 2 Clinical Trial for the treatment of EPI in patients with Cystic Fibrosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TOTUM-63
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Nestle Health Sciences SA
Deal Size: $67.1 million Upfront Cash: $5.1 million
Deal Type: Partnership February 05, 2020
Details:
Partnership secures funding for the development and commercialization of TOTUM-63. Agreement also includes TOTUM-63 supply to Nestlé Health Science.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
